Division of Genetic Medicine and Clinical Pharmacology Archive — Page 6 of 12
-
May 24, 2023
Researchers probe the impact of sex and gender on human health
Vanderbilt University Medical Center's Lea Davis, PhD, and longtime colleagues Ekaterina (Katya) Khramtsova, PhD, and Barbara Stranger, PhD, are among seven authors of a paper published May 11 in the journal Cell that outlines “best practices” for evaluating the impact of both sex and gender on human health. -
May 18, 2023
New view of mutations informs disease risk, treatment response
A transcontinental research effort led by scientists from Vanderbilt University Medical Center and the University of Michigan has upended some long-standing assumptions about mutations — how often they occur, what causes them and what they do. -
May 9, 2023
Neural networks probe proteins
A machine learning method based on neural networks outperformed a mutational scanning model at identifying disease-causing mutations in an Alzheimer’s disease protein, suggesting the method could be useful for facilitating therapeutic design. -
April 20, 2023
Genetics and chronic pain
Polygenic risk scores — scores that reflect the influence of common genetic variants — could be used to predict the likelihood of developing chronic overlapping pain conditions and guide biomarker and targeted prevention efforts. -
April 12, 2023
Research identifies new target that may prevent blood cancer
An international coalition of biomedical researchers co-led by Vanderbilt's Alexander Bick, MD, PhD, has determined a new way to measure the growth rate of precancerous clones of blood stem cells that one day could help doctors lower their patients’ risk of blood cancer. -
March 28, 2023
Inflammation implicated in exfoliation syndrome
Computational genetics tools have implicated inflammatory pathways in exfoliation syndrome, the most common cause of secondary glaucoma, which can result in blindness. -
March 16, 2023
Study evaluates polygenic risk score for prostate cancer risk prediction
A Vanderbilt study found that prostate cancer polygenic risk score has limited utility for enhancing prostate cancer screening.